Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01TVQ
|
||||
| Former ID |
DAP000383
|
||||
| Drug Name |
Ibritumomab
|
||||
| Synonyms |
Zevalin (TN)
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Non-hodgkin's lymphoma [ICD10:C85] | Approved | [1] | ||
| Mantle cell lymphoma [ICD9: 200.4, 202.8, 203.0, 208.9; ICD10:C81-C86, C85.7, C90.0, C91-C95] | Phase 2 | [2], [3] | |||
| Therapeutic Class |
Anticancer Agents
|
||||
| Company |
Bayer Pharmaceuticals Corporation
|
||||
| Formula |
C6382H9830N1672O1979S54
|
||||
| CAS Number |
CAS 174722-31-7
|
||||
| SuperDrug ATC ID |
V10XX02
|
||||
| Target and Pathway | |||||
| Target(s) | B-lymphocyte antigen CD20 | Target Info | [4] | ||
| KEGG Pathway | Hematopoietic cell lineage | ||||
| References | |||||
| REF 1 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
| REF 2 | Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm. 2003 Apr;18(2):165-78. | ||||
| REF 3 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6777). | ||||
| REF 4 | Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11-12):2419-23. Epub 2009 May 8. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.